

Lax NZ, Grady J, Laude A, Chan F, Hepplewhite PD, Gorman G, Whittaker RG, Ng Y, Cunningham MO, Turnbull DM. [Extensive respiratory chain defects in inhibitory interneurons in patients with mitochondrial disease.](#)

*Neuropathology and Applied Neurobiology* 2015, 10.1111/nan.12238

**Copyright:**

© 2015 The Authors. *Neuropathology and Applied Neurobiology* published by John Wiley & Sons Ltd on behalf of British Neuropathological Society.

**DOI link to article:**

<http://dx.doi.org/10.1111/nan.12238>

**Date deposited:**

16/07/2015



This work is licensed under a [Creative Commons Attribution 4.0 International License](#)

# Extensive respiratory chain defects in inhibitory interneurons in patients with mitochondrial disease

N. Z. Lax\*, J. Grady\*, A. Laude†, F. Chan‡, P. D. Hepplewhite\*, G. Gorman\*, R. G. Whittaker‡§, Y. Ng\*, M. O. Cunningham‡ and D. M. Turnbull\*

\*Wellcome Trust Centre for Mitochondrial Research, Institute of Neuroscience, †Bio-imaging Unit, ‡Institute of Neuroscience, Newcastle University, §Department of Clinical Neurophysiology, Royal Victoria Infirmary, Newcastle upon Tyne, UK

N. Z. Lax, J. Grady, A. Laude, F. Chan, P. D. Hepplewhite, G. Gorman, R. G. Whittaker, Y. Ng, M. O. Cunningham and D. M. Turnbull (2015) *Neuropathology and Applied Neurobiology*

## Extensive respiratory chain defects in inhibitory interneurons in patients with mitochondrial disease

**Aims:** Mitochondrial disorders are among the most frequently inherited cause of neurological disease and arise due to mutations in mitochondrial or nuclear DNA. Currently, we do not understand the specific involvement of certain brain regions or selective neuronal vulnerability in mitochondrial disease. Recent studies suggest  $\gamma$ -aminobutyric acid (GABA)-ergic interneurons are particularly susceptible to respiratory chain dysfunction. In this neuropathological study, we assess the impact of mitochondrial DNA defects on inhibitory interneurons in patients with mitochondrial disease. **Methods:** Histochemical, immunohistochemical and immunofluorescent assays were performed on post-mortem brain tissue from 10 patients and 10 age-matched control individuals. We applied a quantitative immunofluorescent method to interrogate complex I and IV protein expression in mitochondria within GABAergic interneurone populations in the frontal, temporal and occipital cortices. We also

evaluated the density of inhibitory interneurons in serial sections to determine if cell loss was occurring. **Results:** We observed significant, global reductions in complex I expression within GABAergic interneurons in frontal, temporal and occipital cortices in the majority of patients. While complex IV expression is more variable, there is reduced expression in patients harbouring m.8344A>G point mutations and *POLG* mutations. In addition to the severe respiratory chain deficiencies observed in remaining interneurons, quantification of GABAergic cell density showed a dramatic reduction in cell density suggesting interneurone loss. **Conclusions:** We propose that the combined loss of interneurons and severe respiratory deficiency in remaining interneurons contributes to impaired neuronal network oscillations and could underlie development of neurological deficits, such as cognitive impairment and epilepsy, in mitochondrial disease.

**Keywords:** cognition, epilepsy, interneurons, mitochondrial DNA, respiratory chain deficiency.

Correspondence: Doug M. Turnbull, Wellcome Trust Centre for Mitochondrial Research, Institute of Neuroscience, The Medical School, Newcastle University, Newcastle upon Tyne, NE2 4HH, UK. Tel: +44(0)1912228565; Fax: +44(0)1912824373; E-mail: doug.turnbull@newcastle.ac.uk

## Introduction

Mitochondrial diseases are heterogeneous disorders characterized by a wide-ranging spectrum of clinical symptoms and fluctuating disease progression. Mitochondrial diseases are the result of primary respiratory chain dysfunction caused by either mitochondrial (mtDNA) or

nuclear DNA mutations. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke-like episodes and dementia and depend on the part of the nervous system affected [1]. Though recent neuropathological studies are expanding our understanding of neural impairment and cell loss in the brains of patients with mitochondrial disease, the mechanisms contributing to specific pathological processes remain to be elucidated.

Recent electrophysiological studies suggest fast-spiking,  $\gamma$ -aminobutyric acid (GABA)-ergic inhibitory interneurons are particularly vulnerable to disruption of complexes I and IV of the mitochondrial respiratory chain [2,3]. This is not surprising as fast-spiking inhibitory interneurons are thought to consume much more energy than other cell types in the brain, and this increased energy requirement originates from their ability to generate and sustain repetitive, high-frequency action potentials that control complex neuronal network oscillations, known as gamma oscillations. Compared with pyramidal neurons that only display intermittent firing patterns, interneurons have elevated firing patterns which are required to support a greater metabolic load through maintenance of ionic homeostasis. Anatomical studies support the notion of a functional heterogeneity of interneurons with respect to metabolic demands. Interneurons contain a high density of mitochondria and are enriched with cytochrome *c* oxidase (COX) and cytochrome *c*; this is likely to reflect the importance of oxidative phosphorylation in supporting their high metabolic capacity [4,5].

In the current study, we aim to establish the degree to which GABAergic inhibitory interneurons are affected by mitochondrial respiratory chain deficiencies and to determine the extent of interneurone loss in post-mortem brain tissues from patients with mitochondrial disease.

## Methods

### Clinical assessment of patients

We investigated a total of 10 adult patients with genetically and clinically well-defined mitochondrial disease who donated their brain for research purposes upon their

death. These patients harboured different genetic defects including m.3243A>G mutation ( $n = 4$ ), m.8344A>G mutation ( $n = 2$ ), single large-scale mtDNA deletion ( $n = 1$ ) and autosomal recessive *POLG* mutations ( $n = 3$ ). We retrospectively analysed the clinical course which was typically assessed using a validated rating scale, Newcastle Mitochondrial Disease Adult Rating Scale (NMDAS) [6], and were therefore able to document neurological deficits including ataxia, stroke-like episodes, epilepsy and cognitive decline (Table 1). None of the patients included in this study died from their epilepsy (Table S1).

### Post-mortem brain tissue

Brain tissues were processed for neuropathological examination as previously described [11], with one hemisphere snap-frozen and the other fixed in formalin and paraffin-embedded. In addition to the 10 brains from patients with mitochondrial disease, 10 age-matched controls with no antecedent history of seizures or strokes were included to allow a direct comparison (Table S1). There were no significant differences in either the age at death ( $t$ -test  $P = 0.9499$ ) or post-mortem interval (PMI;  $t$ -test  $P = 0.5567$ ). Ethical approval for this study was provided by the Newcastle and North Tyneside Local Research Ethics Committee.

To examine the interneuronal populations in these patients, we focussed our investigations on the following brain regions: frontal lobe (Brodmann area 9 – dorsolateral prefrontal cortex), temporal lobe (Brodmann area 21 – inferior temporal cortex) and occipital lobe (Brodmann area 17 – primary visual cortex) in 10 patients and 10 controls. Brain regions of interest (ROIs) were selected on the basis of recognized lobar predilection of pathological involvement in the different genotypes including occipital lobe which is commonly involved in patients harbouring *POLG* mutations, and temporal cortex in patients with m.3243A>G mutations while the frontal cortices are often described as relatively spared and hence used as a relative control ROI.

### Sequential COX and succinate dehydrogenase histochemistry

Sequential COX and succinate dehydrogenase (SDH) histochemistry were performed on three non-serial frozen sections as previously described [12]. This allows

**Table 1.** A detailed clinical summary of all patients included in the current study including evidence of migraine, stroke-like episodes and epilepsy

Patient	Age at death (years)	Gender	Genetic defect	Symptoms	Stroke-like episodes	Epilepsy	Cognitive impairments	Electroencephalogram abnormalities	Neuropathology	Publications
Patient 1	60	F	m.3243A>G	MELAS; ataxia, dementia, deafness, diabetes, cardiomyopathy	+	+	+	Occasional burst of irregular theta activities in both temporal lobes	Microinfarcts affecting cerebellar cortex and 70% Purkinje cell loss. High levels of complex I deficiency in remaining neurones and vascular COX deficiency were reported.	Lax <i>et al.</i> [7,8]
Patient 2	20	F	m.3243A>G	MELAS; ataxia, dementia, deafness	+	+	+	Not available	Numerous microinfarcts affecting cerebellar cortex: 40% of remaining Purkinje cell demonstrated complex I deficiency while COX-deficient and mineralized blood vessels are evident: 5% of substantia nigra neurones are complex I and IV deficient.	Lax <i>et al.</i> and Reeve <i>et al.</i> [7–9]
Patient 3	45	M	m.3243A > G	MELAS; ataxia, dementia	+	+	+	Not available	Microinfarcts involving the cerebellar cortex. 59% and 26% cell loss from Purkinje cell and dentate nucleus neuronal populations. 50% and 30% of remaining Purkinje cells and dentate nucleus neurones are complex I deficient, respectively.	Lax <i>et al.</i> [7,8]
Patient 4	36	F	m.3243A>G	MELAS; ataxia, deafness, constipation, cardiomyopathy, dementia	+	+	+	Encephalopathic	Microinfarcts affecting the cerebellar cortex with 42%, 59% and 56% of inferior olivary neurones, Purkinje cells and dentate nucleus neurones are lost. Complex I and IV deficiency was detected in 40% and 10% of remaining Purkinje cell and dentate nucleus neurones, respectively. Vascular COX deficiency was detected in conjunction with extrusion of plasma proteins into the brain parenchyma.	Lax <i>et al.</i> [7,8]
Patient 5	42	F	m.8344A>G	MERRF; ataxia, peripheral neuropathy, deafness, respiratory failure, dementia	–	+	+	Not available	High degree of neuronal cell loss from the olivo-cerebellar pathway with 85% neurones lost from the inferior olives. High levels of complex I and moderate complex IV deficiencies detected in remaining neurones. COX-deficient vasculature was also observed.	Lax <i>et al.</i> and Reeve <i>et al.</i> [7–9]
Patient 6	58	M	m.8344A>G	MERRF; ataxia, peripheral neuropathy, areflexia, dementia	+	+	+	Encephalopathic	Vascular COX deficiency observed in blood vessels throughout the cerebellum. Low levels of respiratory chain deficiency detected in Substantia nigra neurones.	Lax <i>et al.</i> and Reeve <i>et al.</i> [8,9]
Patient 7	40	F	Single large-scale mtDNA deletion	KSS, ataxia, dementia	–	–	+	Encephalopathic	Spongiform degeneration and loss of myelin proteins including myelin-associated glycoprotein, attributed to respiratory chain deficiency affecting mature oligodendrocytes. 52%, 60% and 23% of olivary neurones, Purkinje cells and dentate nucleus neurones are lost. High levels of complex I deficiency affecting remaining neurones in dentate nucleus and Substantia nigra.	Lax <i>et al.</i> and Reeve <i>et al.</i> [7–10]
Patient 8	24	F	POLG (p.A467T and p.W748S and polymorphic variant: p.E1143G)	Epilepsy; ataxia, CPEO, cognitive decline	+	+	+	Encephalopathic, right posterior quadrant spike/wave	Severe myelin loss from the posterior spinal funiculus.	Lax <i>et al.</i> and Reeve <i>et al.</i> [7–9,11]
Patient 9	55	M	POLG (p.W748S and p.R1096C and polymorphic variant: p.E1143G)	CPEO; ataxia, tremor, dementia	–	+	+	Encephalopathic, multifocal spikes	Severe neuronal cell loss from the olivo-cerebellar pathway and high levels of complex I deficiency in remaining neurones. Severe neurone loss from Substantia nigra. Not previously reported.	
Patient 10	79	M	POLG (p.T251I; p.P587L and p.A467T).	CPEO; ataxia	–	–	–	Not investigated	Not previously reported.	

Limited clinical information was available for patients 2 and 3. MELAS, mitochondrial encephalopathy lactic acidosis and stroke-like episodes; MERRF, myoclonic epilepsy ragged red fibres.

visualization of COX-deficient, SDH-positive neurones (blue staining) and the COX-positive neurones (brown staining). All neurones within 10 mm<sup>2</sup> grey matter band were counted and classified as COX-deficient (or COX intermediate which are defined as partially COX deficient and have a blue–grey appearance) or COX positive. From this data, the percentage COX-deficient neurones were determined.

### Immunofluorescent identification of respiratory chain-deficient GABAergic interneurones

As COX/SDH histochemistry only provides information about COX-deficient SDH-positive cells, we developed an immunofluorescent assay to specifically label GABAergic neurones using glutamic acid decarboxylase 65–67 (GAD65–67), a commonly affected nuclear-encoded subunit of complex I [NADH dehydrogenase (ubiquinone) 1 beta subcomplex subunit 8 (NDUFB8)], a mitochondrially encoded subunit of complex IV [COX subunit 1 (COX1)] and a marker of mitochondria (porin). This was performed on one 5 µm formalin-fixed paraffin-embedded (FFPE) section from frontal, temporal and occipital cortex from each individual patient and control, and a similar method has been described previously [13]. Our procedure briefly involves deparaffinization and rehydration of the sections followed by antigen retrieval by immersion in 1 mmol EDTA pH 8 in a pressure cooker for 40 min and washing in distilled water. Sections were blocked in tris-buffered saline with 1% tween-20 (TBST) containing 10% goat serum for 2 h at room temperature. Mouse monoclonal antibodies against NDUFB8 (Abcam UK Ab110242; diluted 1:100), COX1 (Abcam UK Ab14705; diluted 1:200), porin (Abcam UK Ab14734; diluted 1:200) and a rabbit polyclonal antibody directed against GAD65–67 (Sigma UK G5163; diluted 1:1000) diluted in 10% goat serum made up TBST and incubated overnight at 4°C. This was followed by three washes in TBST, and then IgG subtype-specific secondary anti-mouse antibodies conjugated with Alexa Fluor 488, 546 and 647 (Life Technologies, UK) and a secondary anti-rabbit Alexa Fluor 405 (Life Technologies, UK) antibody diluted 1:100 in 10% goat serum made up in TBST. These were incubated with the sections for 2 h at 4°C. Following this, sections were washed in three washes of TBST and then incubated in 0.3% Sudan Black for 10 min. This was followed by washing in distilled water and mounting in Prolong Gold (Life Technologies, UK).

### Imaging and densitometric analysis

Imaging of stained sections was performed using the epifluorescence Axio Imager M1 (Zeiss) microscope. Inhibitory interneurones were identified by GAD65–67-positive staining, and >40 neurones per case were imaged independent of cellular morphology or protein abundance. For densitometric analysis of the target proteins, IMAGE J software (U. S. National Institutes of Health, Bethesda, Maryland, USA, version 1.46r) was used, and images from the four channels were imported as an image sequence. The background signal for all antibodies was determined in a no primary control section. Cells were outlined manually according to their GAD65–67 signal. Within these defined areas, mean signal intensities of all channels were determined simultaneously using the 'analyse stack' function in IMAGE J and an optical density (OD) value derived.

### Statistics

The background-corrected OD values were not normally distributed and therefore required square root transformation to normalize the data. Linear regression of transformed NDUFB8 (NDUFB8<sup>T</sup>) data against transformed porin (porin<sup>T</sup>) data and transformed COX1 (COX1<sup>T</sup>) data against porin<sup>T</sup> data was performed to ensure the residuals of the regression were normally distributed, and the standard error of estimate was determined. For each interneurone, the *z* score for the porin (porin<sup>z</sup>) was calculated, and the scores for NDUFB8 (NDUFB8<sup>z</sup>) and COX1 (COX1<sup>z</sup>) were derived by using the linear regression based on the level of porin. Finally, interneurones were classified based on standard deviation limits (for NDUFB8 or COX1: normal if *z* > −2SD, low if *z* < −2SD, deficient if *z* < −3SD and very deficient if *z* < −4SD). All statistical analyses were carried out using SAS 9.3 (SAS Institute Inc., Cary, NC, USA).

### Immunohistochemical staining and two-dimensional neurone counting

FFPE frontal, temporal and occipital tissues were acquired and stained for identification of GABAergic inhibitory interneurones (anti-GAD65–67; Sigma 1:000) using a polymer kit and visualization with DAB as previously described [11]. A two-dimensional neuronal cell counting protocol was employed as previously described with slight



modification [7]. Briefly, an area of at least 20  $\mu\text{m}^2$  was outlined along a cortical ribbon encompassing cellular layers I – VI at  $\times 2$  magnification within each Brodmann area. As ischaemic-like lesions were frequent in these patients, only unaffected areas of the cortex were quantified. Positive neurones as identified by dark brown chromogen staining within this area were counted at  $\times 40$  magnification and the neuronal cell densities (given as number per square millimeter) calculated for each region. This was performed on two sections separated by at least 30  $\mu\text{m}$ . To determine percentage interneurone cell loss, the mean for each patient was divided by the mean interneurone density from all controls; this value was then multiplied by 100 to give percentage cell density of control. The percentage cell loss was then calculated by 100% cell density.

### Molecular biology to quantify mutation load in homogenate tissues

The percentage heteroplasmic mutant load was determined by pyrosequencing for specific point mutations in homogenate frozen frontal, temporal or occipital tissues as previously described [7].

## Results

### Neurological manifestations in patients

Clinical symptoms including neurological impairments are summarized where available by Table 1. In this study, all patients investigated displayed encephalopathic findings on electroencephalogram investigation. Eight of 10 patients had epilepsy which took a variety of forms including focal and generalized tonic-clonic or myoclonic seizures. The patient harbouring a single large-scale mtDNA deletion (patient 7) did not have epilepsy which is entirely consistent with previous reports in the literature [14], and the other patient (patient 10) that did not have epilepsy harboured *POLG* mutations and had a primarily chronic progressive external ophthalmoplegia (CPEO) phenotype and was elderly when he died. Stroke-like episodes were also common and featured in six patients of which four patients harboured the m.3243A>G mutation, one patient harboured the m.8344A>G mutation (patient 6) and one harboured autosomal recessive mutations in *POLG* (patient 8). Patients showed signs of cognitive


decline or dementia which are prominent features in patients with mitochondrial disease.

### COX deficiency in CNS tissues

Sequential COX/SDH histochemistry reveals the presence of COX-deficient cells throughout the CNS (Figure 1). The long PMI for patient 2 did not appear to negatively affect either COX or SDH enzyme activity in all CNS regions assayed; though COX activity was certainly deficient in some neurones, there were multiple neurones which demonstrated high activity (strong DAB reaction product), while SDH activity was high in neurones and blood vessels that were COX-deficient. Analysis of the frontal, temporal and occipital tissues highlights COX-deficiency present in neurones. Quantification of the percentage of neurones harbouring COX-deficiency revealed the highest percentage of COX-deficient neurones in patients harbouring m.8344A>G, while other patients had COX-deficient neurones at lower levels (summarized in Table 2). Almost all patients (including those harbouring *POLG* mutations) demonstrated COX-deficiency within blood vessels and white matter tracts. Although this provides information about the distribution and extent of COX-deficiency, this method is limited as it does not distinguish exactly which cells are most vulnerable and assessment of COX/SDH histochemistry is subjective.

### Respiratory chain deficient inhibitory interneurones

We defined respiratory chain deficiency as a loss or reduced immunoreactivity of either NDUFB8 or COX1 proteins, despite high immunoreactivity of porin for mitochondria within a GABAergic inhibitory interneurone cell body. Throughout all cortical regions assessed, we detected a range of respiratory chain deficiencies within GABAergic interneurones by quadruple immunofluorescent staining (Figure 2). We visually confirmed that control GABAergic neurones showed co-localization of NDUFB8, COX1 and porin implying intact mitochondrial respiratory chain protein expression in these cells. However, in patient tissues, there was an obvious lack of co-localization due to a loss of NDUFB8 and COX1 expression despite high expression of porin in GABAergic interneurones. It was clear that the inhibitory interneurone populations exhibit respiratory chain deficiencies to varying levels in all CNS regions in all patients.



**Figure 1.** Sequential COX/SDH histochemistry reveals COX-positive (brown) cells are present in the CNS of a control individual, while patient CNS tissues reveal a mosaic pattern of COX-positive and COX-deficient (blue) cells. Here, representative images have been captured from control, patient with m.3243A>G (patient 3), patient with m.8344A>G (patient 6) and patient with mutations in *POLG* (patient 9) grey matter and white matter regions in the occipital lobe. Control tissues demonstrate COX-positive (respiratory normal) cells throughout all regions investigated, while patient tissues show both COX-positive and COX-deficient cells affecting neurones, blood vessels and glia. Scale bar = 100  $\mu$ m.

NDUFB8 expression was typically more affected than COX1 indicating more complex I deficiency though this pattern was variable. Patients harbouring the m.3243A>G mutation and single large-scale mtDNA deletion showed a more specific loss or reduced expression of NDUFB8 while COX1 expression appears relatively intact. Patients harbouring the m.8344A>G point mutation or *POLG* mutations showed combined deficiencies of complexes I and IV (Figure 2). Loss of NDUFB8 and COX1 expression may occur with increased porin levels in patient interneurons (Figure 2).

Quantification of OD for NDUFB8, COX1 and porin was performed within each GAD65-67 positive neuronal cell body, and to determine respiratory chain deficiency, the OD data were transformed with linear regression for NDUFB8 vs. porin and COX1 vs. Porin, and *z* scores were derived (as shown in Figure 3). In this study, we used negative *z* scores of magnitude 3 or less to indicate respira-

tory chain deficiency, and based on this, we determined the percentage of interneurons exhibiting respiratory chain deficiency (Table 3).

Our quantitative data show interneurons display prominent deficiencies for complex I in almost all patients with fewer complex IV-deficient cells throughout all three CNS regions investigated (Figure 3 and Table 3). In agreement with visual observations, interneurons sampled from patients harbouring the m.3243A>G mutation exhibit the greatest deficiency for NDUFB8, while COX1 involvement is minimal (Table 3). Quantification shows evidence of combined complex I and IV deficiency in patients harbouring m.8344A>G (patient 5) and *POLG* mutations (patient 8 and 9). Intriguingly, patient 10 (*POLG*) demonstrates very mild respiratory chain deficiency in interneurons with most being preserved, though it is important to note this patients' clinical course was mild and he had a CPEO phenotype, whereas patient 8

**Table 2.** COX deficiency throughout the frontal, temporal and occipital cortices

<i>Patient</i>	<i>% COX-deficient neurones</i>	<i>COX-deficient neuropil</i>	<i>COX-deficient cells in white matter</i>	<i>COX-deficient blood vessels</i>
Frontal cortex				
Patient 1	0	No	No	No
Patient 2	37	Yes	Yes	Yes
Patient 3	10	No	No	Yes
Patient 5	62	Yes	Yes	Yes
Patient 6	59	Yes	*	Yes
Patient 7	2	No	Yes	Yes
Temporal cortex				
Patient 1	2	No	Yes	Yes
Patient 2	26	Yes	Yes	Yes
Patient 3	37	Yes	Yes	Yes
Patient 5	64	Yes	Yes	Yes
Patient 6	82	Yes	Yes	Yes
Patient 7	8	Yes	Yes	Yes
Occipital cortex				
Patient 3	24	Yes	Yes	Yes
Patient 5	75	Yes	Yes	Yes
Patient 6	88	Yes	Yes	Yes
Patient 7	27	Yes	Yes	Yes
Patient 8	27	Yes	Yes	Yes
Patient 9	36	Yes	Yes	Yes
Patient 10	36	Yes	Yes	Yes

\*There was no white matter present on the frontal lobe section obtained for patient 6, and therefore, this could not be assessed.

**Table 3.** Percentage of GABAergic interneurons exhibiting complex I and IV deficiency

	<i>Controls</i>	<i>Patient 1</i>	<i>Patient 2</i>	<i>Patient 3</i>	<i>Patient 4</i>	<i>Patient 5</i>	<i>Patient 6</i>	<i>Patient 7</i>	<i>Patient 8</i>	<i>Patient 9</i>	<i>Patient 10</i>
Frontal cortex											
% NDUF8 deficiency	0.3	73	89	47	75	96	36	69	100	96	2
% COX1 deficiency	0.2	5	0	0	0	45	5	3	8	17	0
Temporal cortex											
% NDUF8 deficiency	0	69	79	18	66	40	21	33		37	0
% COX1 deficiency	0.5	4	16	0	5	15	5	2		4	0
Occipital cortex											
% NDUF8 deficiency	0			50	100	79	68	100	100	94	9
% COX1 deficiency	0			0	98	49	17	39	100	33	4


(POLG) had an early-onset, Alpers'-like devastating disease course.

### GABAergic interneurone cell loss in mitochondrial disease

We demonstrated that GABAergic cell density is reduced throughout all cortical regions assessed in the majority of patients relative to their control counterparts (Figure 4). Quantification of GAD65-67-positive cells and therefore GABAergic cell density revealed a reduction in all regions examined suggesting widespread and, in some patients, a high percentage (>50%) loss of GABAergic cells through-

out the CNS (Figure 4 and Table 4). This analysis did not reveal that any particular CNS region was more vulnerable than another. There is also variability in the immunoreactivity for GAD65-67 with the majority of patients revealing a loss of positive staining in neuritic processes which implies that inhibitory neurotransmission may be affected. We evaluated whether there was a correlation between respiratory chain deficiency involving complex I and complex IV and the percentage of interneurone loss. Though there was a positive trend with increasing cell loss and increased respiratory chain deficiency in remaining cells, this did not reach statistical significance (Spearman's rank correlation coefficient).






**Figure 2.** Quadruple immunofluorescence allows visualization of mitochondrial respiratory chain proteins including complexes I and IV in conjunction with mitochondrial mass within GABAergic interneurons in the inferior temporal lobe. Here, representative images have been captured of GABAergic inhibitory interneurons (GAD65-67-positive cells which are delineated by white dashed line) from control, m.3243A>G, m.8344A>G and *POLG* individuals in the inferior temporal cortex. Control GABAergic interneurons show equal expression of complex I (NDUFB8) and complex IV (COX1) and mitochondria (porin) which colocalize in the merged image. In m.3243A>G, there is a specific loss of NDUFB8, while COX1 and porin remain intact. Both m.8344A>G and *POLG* show a combined loss of NDUFB8 and COX1 while mitochondrial density is high. Scale bar = 10  $\mu$ m.

### Percentage mutant load in frontal, temporal and occipital homogenates

Percentage m.3243A>G and m.8344A>G mutation loads determined in homogenate tissues are shown in Table 5. Molecular analysis showed that the level of mutation did not vary across the three brain regions and was greater than 79% in all patients analysed.


### Discussion

We investigated the neuropathology of 10 adult patients with mitochondrial disease to determine whether inhibitory interneurons are particularly vulnerable to mtDNA defects and could feasibly contribute to altered neuronal network circuitry in the brain. Using a quadruple immunofluorescent technique, we provide clear evidence



**Figure 3.** Extensive respiratory chain deficiency involving complex I and to a lesser degree complex IV is evident in GABAergic interneurons throughout the CNS in patients with mitochondrial disease. Data represents z scores derived from the quantitative assessment of NDUF8 and COX1 optical densities relative to porin optical densities within GABAergic interneurons in patients and controls. The data show how much the complex I and IV expression (relative to porin) deviates from normality. Here, a z score of  $-2$  to  $+2$  indicates normal expression (dashed blue lines demonstrate upper and lower limits of normal expression), while a z score above  $2$  indicates higher expression, and a z score lower than  $-2$  indicates reduced expression. There is marked complex I deficiency, while complex IV deficiency is only slight in comparison in all patient interneurons.





**Figure 4.** GABAergic interneurone loss is evident in frontal, temporal and occipital cortices in patients with mitochondrial disease relative to age-matched controls. Quantification of GAD65-67-positive cells in frontal (A), temporal (B) and occipital (C) cortices are shown as bars with mean  $\pm$  standard deviation. In all patients, there is a clear reduction in the density of GABAergic interneurons in all brain regions assessed. In addition to reduced number of GAD65-67-positive cells, there is also variability in immunoreactivity with a propensity towards reduced expression within the neurites of patients' tissues relative to controls. Scale bar = 100  $\mu$ m.

**Table 4.** Percentage of GABAergic neurone cell loss in patients (patient neurone density/average control neurone density  $\times 100$ )

Patient	Frontal cortex (%)	Temporal cortex (%)	Occipital cortex (%)
Patient 1	58	67	Not available
Patient 2	81	62	Not available*
Patient 3	74	49	67
Patient 4	72	50	87
Patient 5	81	68	70
Patient 6	59	73	67
Patient 7	0	39	44
Patient 8	96	92	81
Patient 9	68	82	88
Patient 10	52	63	60

\*Data for patient 2 are not available as the occipital cortex was completely devastated by a necrotic ischaemic-like lesion.

**Table 5.** Percentage mutant load in homogenate CNS tissues

Patient	Frontal cortex	Temporal cortex	Occipital cortex
Patient 1	79	83	Not available
Patient 2	93	93	94
Patient 3	90	94	92
Patient 5	92	92	93
Patient 6	87	88	88

of combined respiratory chain deficiencies involving complexes I and IV, despite high mitochondrial mass, in GABAergic interneurons throughout the CNS of patients with mitochondrial disease. The overall density of GABAergic interneurons is reduced in many of these patients, implying reduced inhibitory neurotransmission which could contribute to altered network dynamics in the brains of patients. This raises the possibility that a loss of inhibitory interneurons might lower the amount of inhibitory activity in the brain and could contribute to phenotypes, including epilepsy and cognitive decline.

Recent electrophysiological evidence implicates a vulnerability of fast-spiking inhibitory interneurons to perturbed energy metabolism [2,3,15]. The evidence for this vulnerability stems from the high energy requirement of these cells to produce complex, high-frequency action potentials allowing them to exert local control over large populations of pyramidal neurones. Inhibitory GABAergic interneurons modulate excitation and inhibition in the cerebral cortex [16] and thereby contribute to local control of microcircuitry, shaping information

outputs from the excitatory pyramidal neurones which transmit information throughout the brain to different cortical areas. The balance of excitation and inhibition is crucial, and without this, the threshold for developing pathological conditions, such as epilepsy or impaired cognition, might be lowered. Indeed, dysfunction or a loss of GABAergic interneurons has been recognized as a potential contributor to lowering seizure threshold [17–19]. This work shows that there is indeed widespread mitochondrial respiratory chain deficiency in inhibitory interneurons in patients with mitochondrial disease, and this might contribute to altered network dynamics in the brains of these patients.

In this study, we used a quadruple immunofluorescent approach to accurately quantify respiratory chain deficiency by measuring complex I and IV subunit expression in conjunction with mitochondrial mass in GABAergic interneurone populations in patients with mitochondrial disease. This method provides an unbiased, reproducible, precise and detailed analysis of mitochondrial respiratory chain deficiency which can be modified to include other subunits of the mitochondrial respiratory chain or used to evaluate different cell types. Our data reveal extensive respiratory chain deficiencies affecting inhibitory interneurons, with a marked reduction in complex I and IV expression in patients with mitochondrial disease relative to age-matched controls. Complex I deficiency exceeds complex IV deficiency which is a consistently reported neuropathological finding in patients with mitochondrial disease [20,21] and is a common pathological finding in other neurological disorders, including Parkinson's disease [22] and temporal lobe epilepsy [23].

We next investigated interneurone population density to determine the impact of respiratory chain deficiency on interneurone cell loss. We observed a widespread and extensive decrease in interneurone density throughout all brain regions analysed in the majority of patients. An exception to this is patient 7 (single mtDNA deletion) where the density of interneurone was similar to control densities in frontal cortex, and higher than in other patients in temporal and occipital cortices. All quantification was performed in areas of the cortex that were spared and did not show features consistent with laminar dehiscence or necrotic lesions. What is interesting is the trend towards interneurone loss, affecting all regions including the frontal cortex. Pathology in these patients is often described in posterior regions [12,24], though in our clinical experience, frontal lobe involvement is not uncommon.



mon. In fact, ischaemic-like lesions in frontal lobes were documented in four patients in this study, including patient 1 (m.3243A>G), patient 2 (m.3243A>G), patient 9 (POLG) and patient 10 (POLG) which suggests greater brain involvement than perhaps originally perceived [25,26]. Indeed, high heteroplasmy levels of mutated mtDNA were detected in homogenate DNA extracted from all three brain regions. Interneurone pathology in these frontal regions may also influence other pathological processes recognized in mitochondrial disease, including neuropsychiatric manifestations and cognitive decline [27]. Indeed, cognitive decline has been reported in patients with mitochondrial disease previously [28,29], and a loss of calbindin-positive interneurons is implicated in the development of cognitive impairments in patients harbouring the m.3243A>G mutation [30]. Interneurone cell loss was extensive in the majority of patients but was less severe in patient 7 (single large-scale deletion) and patient 10 (POLG) where GABAergic interneurons were only moderately decreased. Pathology in patients harbouring large-scale mtDNA deletions predominantly results from spongiform degeneration of the white matter tracts and is associated with cerebellar ataxia and cognitive impairment [14,31]. Patient 10 (POLG) presented with mitochondrial disease later in life and principally exhibited a CPEO phenotype without overt neurological involvement, and this may account for why there was very little respiratory chain deficiency in his interneurons and a moderate loss of interneurons.

Our data show extensive involvement of the interneurons in mitochondrial disease, and we believe that interneurone pathology due to respiratory chain deficiency and cell loss might contribute to altered neuronal network dynamics in the brain which is responsible for neurological deficits seen in these patients. Electroencephalogram data from these patients certainly provides evidence in support of impaired neuronal networks in mitochondrial disease, and we believe that interneurone dysfunction and cell loss could be one factor contributing to abnormal neuronal activity. In those patients where interneurone loss is high it is interesting to note that the clinical course was generally dominated by severe neurological impairments including stroke-like episodes, seizures and cognitive decline. Although other factors, such as mitochondrial dysfunction in other cell types, may contribute and certainly may have an additive effect on development and severity of neurological disease. Certainly, COX/SDH histochemistry reveals that COX-deficiency

affects multiple cell types including neurones, vascular and glial cells (Figure 1). The contribution of mitochondrial impairments in these cells may modify neuronal network oscillations and may be an important factor for the development of multiple neurological features, including stroke-like episodes and epilepsy [32]. Therefore, it would be important to assess the degree of mitochondrial impairment in these cells.

Though neuropathological investigation of post-mortem brain tissue from patients with mitochondrial disease is limited as pathology often represents end-stage disease and patients with severe end-stage disease are much more likely to have had severe neurological conditions, we believe this study has provided clear evidence of mitochondrial dysfunction in GABAergic interneurons. We believe interneurone dysfunction is an important finding and might be one of the pathological processes contributing to altered neuronal oscillations to promote development of impaired neurological function in these patients. This work offers an important platform from which further work can be completed to understand how mitochondrial respiratory chain deficiencies affect distinct neuronal populations.

## Acknowledgements

This work was supported by The Wellcome Trust (074454/Z/04/Z), UK NIHR Biomedical Research Centre for Ageing and Age-Related disease award to the Newcastle upon Tyne Hospitals NHS Foundation Trust and the UK NHS Specialist Commissioners which funds the 'Rare Mitochondrial Disorders of Adults and Children' Diagnostic Service in Newcastle upon Tyne (<http://www.mitochondrialncg.nhs.uk>). Tissue for this study was provided by the Newcastle Brain Tissue Resource which is funded in part by a grant from the UK Medical Research Council (G0400074) and the MRC Edinburgh Sudden Death Brain Bank.

## Conflict of interest

The authors declare that they have no conflict of interest.

## Author contributions

NZL, MOC and DMT contributed substantially to the conception of the study. NZL, AL and PDH contributed to the design of the study. GG, RGW and YN acquired the clinical

information. NZL acquired the data. NZL and JP performed the data analysis. NZL, JP, GG and DMT contributed to data interpretation, and all authors provided critical revisions and gave their final approval to the manuscript.

## References

- DiMauro S, Schon EA, Carelli V, Hirano M. The clinical maze of mitochondrial neurology. *Nat Rev Neurol* 2013; **9**: 429–44
- Kann O, Huchzermeyer C, Kovacs R, Wirtz S, Schuelke M. Gamma oscillations in the hippocampus require high complex I gene expression and strong functional performance of mitochondria. *Brain* 2011; **134** (Pt 2): 345–58
- Whittaker RG, Turnbull DM, Whittington MA, Cunningham MO. Impaired mitochondrial function abolishes gamma oscillations in the hippocampus through an effect on fast-spiking interneurons. *Brain* 2011; **134** (Pt 7): e180; author reply e1
- Kageyama GH, Wong-Riley MT. Histochemical localization of cytochrome oxidase in the hippocampus: correlation with specific neuronal types and afferent pathways. *Neuroscience* 1982; **7**: 2337–61
- Gulyas AI, Buzsaki G, Freund TF, Hirase H. Populations of hippocampal inhibitory neurons express different levels of cytochrome c. *Eur J Neurosci* 2006; **23**: 2581–94
- Schaefer AM, Phoenix C, Elson JL, McFarland R, Chinnery PF, Turnbull DM. Mitochondrial disease in adults: a scale to monitor progression and treatment. *Neurology* 2006; **66**: 1932–4
- Lax NZ, Hepplewhite PD, Reeve AK, Nesbitt V, McFarland R, Jaros E, Taylor RW, Turnbull DM. Cerebellar ataxia in patients with mitochondrial DNA disease: a molecular clinicopathological study. *J Neuropathol Exp Neurol* 2012; **71**: 148–61
- Lax NZ, Pienaar IS, Reeve AK, Hepplewhite PD, Jaros E, Taylor RW, Kalaria RN, Turnbull DM. Microangiopathy in the cerebellum of patients with mitochondrial DNA disease. *Brain* 2012; **135** (Pt 6): 1736–50
- Reeve A, Meagher M, Lax N, Simcox E, Hepplewhite P, Jaros E, Turnbull D. The impact of pathogenic mitochondrial DNA mutations on substantia nigra neurons. *J Neurosci* 2013; **33**: 10790–801
- Lax NZ, Campbell GR, Reeve AK, Ohno N, Zamboni J, Blakely EL, Taylor RW, Bonilla E, Tanji K, DiMauro S, Jaros E, Lassmann H, Turnbull DM, Mahad DJ. Loss of myelin-associated glycoprotein in Kearns-Sayre syndrome. *Arch Neurol* 2012; **69**: 490–9
- Lax NZ, Whittaker RG, Hepplewhite PD, Reeve AK, Blakely EL, Jaros E, Ince PG, Taylor RW, Fawcett PR, Turnbull DM. Sensory neuronopathy in patients harbouring recessive polymerase gamma mutations. *Brain* 2012; **135** (Pt 1): 62–71
- Betts J, Jaros E, Perry RH, Schaefer AM, Taylor RW, Abdel-All Z, Lightowlers RN, Turnbull DM. Molecular neuropathology of MELAS: level of heteroplasmy in individual neurones and evidence of extensive vascular involvement. *Neuropathol Appl Neurobiol* 2006; **32**: 359–73
- Grunewald A, Lax NZ, Rocha MC, Reeve AK, Hepplewhite PD, Rygiel KA, Taylor RW, Turnbull DM. Quantitative quadruple-label immunofluorescence of mitochondrial and cytoplasmic proteins in single neurons from human midbrain tissue. *J Neurosci Methods* 2014; **232**: 143–9
- Kearns TP, Sayre GP. Retinitis pigmentosa, external ophthalmoplegia, and complete heart block: unusual syndrome with histologic study in one of two cases. *AMA Arch Ophthalmol* 1958; **60**: 280–9
- Kann O, Papageorgiou IE, Draguhn A. Highly energized inhibitory interneurons are a central element for information processing in cortical networks. *J Cereb Blood Flow Metab* 2014; **34**: 1270–82
- Haider B, Duque A, Hasenstaub AR, McCormick DA. Neocortical network activity in vivo is generated through a dynamic balance of excitation and inhibition. *J Neurosci* 2006; **26**: 4535–45
- Marco P, Sola RG, Pulido P, Alijarde MT, Sanchez A, Ramon y Cajal S, DeFelipe J. Inhibitory neurons in the human epileptogenic temporal neocortex. An immunocytochemical study. *Brain* 1996; **119** (Pt 4): 1327–47
- Magloczky Z, Freund TF. Impaired and repaired inhibitory circuits in the epileptic human hippocampus. *Trends Neurosci* 2005; **28**: 334–40
- Hunt RF, Girsakis KM, Rubenstein JL, Alvarez-Buylla A, Baraban SC. GABA progenitors grafted into the adult epileptic brain control seizures and abnormal behavior. *Nat Neurosci* 2013; **16**: 692–7
- Tzoulis C, Tran GT, Coxhead J, Bertelsen B, Lilleng PK, Balafkan N, Payne B, Miletic H, Chinnery PF, Bindoff LA. Molecular pathogenesis of polymerase gamma-related neurodegeneration. *Ann Neurol* 2014; **76**: 66–81
- Hakonen AH, Goffart S, Marjavaara S, Paetau A, Cooper H, Mattila K, Lampinen M, Sajantila A, Lonnqvist T, Spelbrink JN, Suomalainen A. Infantile-onset spinocerebellar ataxia and mitochondrial recessive ataxia syndrome are associated with neuronal complex I defect and mtDNA depletion. *Hum Mol Genet* 2008; **17**: 3822–35
- Schapira AH, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD. Mitochondrial complex I deficiency in Parkinson's disease. *J Neurochem* 1990; **54**: 823–7
- Kunz WS, Kudin AP, Vielhaber S, Blumcke I, Zischratter W, Schramm J, Beck H, Elger CE. Mitochondrial complex I deficiency in the epileptic focus of patients with temporal lobe epilepsy. *Ann Neurol* 2000; **48**: 766–73
- Tzoulis C, Bindoff LA. Acute mitochondrial encephalopathy reflects neuronal energy failure irrespective of which genome the genetic defect affects. *Brain* 2012; **135** (Pt 12): 3627–34
- Engelsen BA, Tzoulis C, Karlsen B, Lillebo A, Laegreid LM, Aasly J, Zeviani M, Bindoff LA. POLG1 mutations cause a

- syndromic epilepsy with occipital lobe predilection. *Brain* 2008; **131** (Pt 3): 818–28
- 26 Brinjikji W, Swanson JW, Zabel C, Dyck PJ, Tracy JA, Gavrilova RH. Stroke and Stroke-Like Symptoms in Patients with Mutations in the POLG1 Gene. *JIMD Rep* 2011; **1**: 89–96
- 27 Anglin RE, Tarnopolsky MA, Mazurek MF, Rosebush PI. The psychiatric presentation of mitochondrial disorders in adults. *J Neuropsychiatry Clin Neurosci* 2012; **24**: 394–409
- 28 Turconi AC, Benti R, Castelli E, Pochintesta S, Felisari G, Comi G, Gagliardi C, Del Piccolo L, Bresolin N. Focal cognitive impairment in mitochondrial encephalomyopathies: a neuropsychological and neuroimaging study. *J Neurol Sci* 1999; **170**: 57–63
- 29 Nearingdard SA, Murtagh MP, Wong B, Hill EK. The neuropsychologic deficits of MELAS: evidence of global impairment. *Cogn Behav Neurol* 2007; **20**: 83–92
- 30 Emmanuele V, Garcia-Cazorla A, Huang HB, Coku J, Dorado B, Cortes EP, Engelstad K, De Vivo DC, Dimauro S, Bonilla E, Tanji K. Decreased hippocampal expression of calbindin D28K and cognitive impairment in MELAS. *J Neurol Sci* 2012; **317**: 29–34
- 31 Oldfors A, Fyhr IM, Holme E, Larsson NG, Tulinius M. Neuropathology in Kearns-Sayre syndrome. *Acta Neuropathol* 1990; **80**: 541–6
- 32 Iizuka T, Sakai F. Pathogenesis of stroke-like episodes in MELAS: analysis of neurovascular cellular mechanisms. *Curr Neurovasc Res* 2005; **2**: 29–45

## Supporting information

Additional Supporting Information may be found in the online version of this article at the publisher's web-site:

Table S1. Characteristics of the patient and control tissue used for this study.

Received 9 January 2015

Accepted after revision 13 March 2015

Published online Article Accepted on 18 March 2015